TY - JOUR AU - Casaluce, Francesca AU - Gridelli, Cesare PY - 2018 TI - Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found? JF - Translational Lung Cancer Research; Vol 7, Supplement 4 (December 30, 2018): Translational Lung Cancer Research Y2 - 2018 KW - N2 - Immunotherapies have been incorporated in the treatment strategy of advanced non-small cell lung cancer (NSCLC), with worldwide pembrolizumab approval as upfront single agent for tumors with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of ≥50%, and recently with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approvals of pembrolizumab in combination with chemotherapy for non-squamous lung cancer, irrespective of PD-L1 status. UR - https://tlcr.amegroups.org/article/view/24459